The advent of a selective 4R tau PET tracer would not only serve as a valuable diagnostic tool for the early diagnosis of PSP and other non‐AD tauopathies but also enable the enrichment of therapeutic trials with individuals in the early stages of the disease and the monitoring of treatment effects. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.